类风湿关节炎下转运体表达及活性的变化

doi:10.12092/j.issn.1009-2501.2018.02.020

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (2): 223-229.doi: 10.12092/j.issn.1009-2501.2018.02.020

类风湿关节炎下转运体表达及活性的变化

杜娟^1,2，徐玲燕¹，吴伟¹，沈青青^1,2，江振洲^1,2,3，张陆勇^1,4，黄鑫^1,2,3

¹中国药科大学江苏省新药筛选重点实验室，南京 210009，江苏；²药物质量与安全预警教育部重点实验室（中国药科大学），南京 210009，江苏；³中国药科大学江苏省药效研究与评价服务中心，南京 210009，江苏； ⁴广东药科大学药学院，新药筛选与药效学评价中心，广州 510006，广东

收稿日期:2017-11-02 修回日期:2018-01-24 出版日期:2018-02-26 发布日期:2018-03-02
通讯作者: 黄鑫，女，博士，副教授，硕士生导师，研究方向：药物体内分析。 Tel：13851799037 E-mail：huangxin@cpu.edu.cn
作者简介:杜娟，女，硕士研究生，研究方向：药物体内分析。 Tel：18360860982 E-mail：18360860982@163.com
基金资助:
国家自然科学基金面上项目(81673684)；国家自然科学基金青年项目(81303301)；江苏省研究生培养创新工程(KYCX17-0718)；国家自然科学基金重大国际（地区）合作研究项目(81320108029)

Changes of transporters expression and activity in rheumatoid arthritis

DU Juan ^1,2, XU Lingyan ¹, WU Wei¹, SHENG Qingqing ^1,2, JIANG Zhenzhou ^1,2,3, ZHANG Luyong ^1,4, HUANG Xin ^1,2,3

¹ Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing 210009, Jiangsu, China; ²Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing 210009, Jiangsu, China; ³Key Laboratory of Quality Control and Pharmacovigilance (China Pharmaceutical University), Nanjing 210009, China;⁴ Center for Drug Screening and Pharmacodynamics Evaluation, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China

Received:2017-11-02 Revised:2018-01-24 Online:2018-02-26 Published:2018-03-02

摘要/Abstract

摘要：

机体发生炎症时会释放大量的炎性细胞因子，并伴随药物转运体表达和活性的改变。转运体的表达和活性改变时，会影响药物的吸收、分布、消除，机体内血药浓度、蓄积情况、药物的治疗有效性等也会发生改变，甚至产生多药耐药、药物-药物相互作用等现象。类风湿关节炎是一种常见的炎症疾病，会释放大量的炎性细胞因子，伴随转运体表达和活性的改变，从而影响治疗效果，因此研究炎症状态下药物转运体表达和活性的改变至关重要。本文就类风湿关节炎下转运体的变化进行综述，以期为类风湿关节炎的治疗提供新的方向。

关键词: 类风湿关节炎, SLC转运体, ABC转运体

Abstract:

Inflammatory disease state will release a large number of inflammatory cytokines, and accompanied by drug transporters expression and activity changes. Drug transporters are present in various tissues and have an important role in drug absorption, distribution, and elimination. Expression and activity changes will affect the body's plasma concentration, accumulation, the effectiveness of drug treatment, and even produce multidrug resistance, drug-drug interactions and so on. Rheumatoid arthritis is a common inflammatory disease that releases a large number of inflammatory cytokines, with changes in expression and activity of the transporters, which affects the therapeutic effect and changes the expression and activity of the drug transporters. This review summarizes the knowledge on the roles of transporters in rheumatoid arthritis in order to provide a new direction for the treatment of rheumatoid arthritis.

Key words: rheumatoid arthritis, SLC transporters, ABC transporters

中图分类号:

R392.5

杜娟，徐玲燕，吴伟，沈青青，江振洲，张陆勇，黄鑫. 类风湿关节炎下转运体表达及活性的变化[J]. 中国临床药理学与治疗学, 2018, 23(2): 223-229.

DU Juan, XU Lingyan, WU Wei, SHENG Qingqing, JIANG Zhenzhou, ZHANG Luyong, HUANG Xin. Changes of transporters expression and activity in rheumatoid arthritis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 223-229.

参考文献

［1］Smolen JS, Aletaha D, Mcinnes IB. Rheumatoid arthritis［J］. Lancet, 2016, 388(10055): 2023.
［2］Okada M, Fujii H, Suga Y, et al. Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis［J］. J Pharm Health Care Sci, 2017, 3(1): 7.
［3］Lee SW, Kim JH, Park MC, et al. Alleviation of rheumatoid arthritis by cell-transducible methotrexate upon transcutaneous delivery［J］. Biomaterials, 2012, 33(5): 1563-1572.
［4］Pavkova GM, Lipkova J, Pavek N, et al. RANTES, MCP-1 chemokines and factors describing rheumatoid arthritis［J］. Mol Immunol, 2012, 52(3-4): 273-278.
［5］Kokkonen H, Sderstrm I, Rocklv J, et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis［J］. Arthritis & Rheum, 2010, 62(2): 383-391.
［6］Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics［J］. Clin Pharmacol Ther, 2009, 85(4): 434-438.
［7］Markova S, Nakamura T, Sakaeda T, et al. Genotype-dependent down-regulation of gene expression and function of MDR1 in human peripheral blood mononuclear cells under acute inflammation［J］. Drug Metab Pharmacokinet, 2006, 21(3): 194-200.
［8］Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution［J］. Eur J Pharm Sci, 2006, 27(5): 425-446.
［9］Morris ME, Rodriguez-Cruz V, Felmlee MA. SLC and ABC transporters: expression, localization, and species differences at the blood-brain and the blood-cerebrospinal fluid barriers［J］. AAPS J, 2017, 19(5):1317-1331
［10］Koepsell H, Endou H. The SLC22 drug transporter family［J］. Pflügers Archiv - European Journal of Physiology, 2004, 447(5): 666-676.
［11］李聃, 盛莉, 李燕. 药物转运体的研究方法［J］. 药学学报, 2014, 49(7): 963-970.
［12］马莉, 饶志, 武新安. 药物转运体在药物排泄中的作用［J］. 中国药学杂志, 2013, 48(8): 582-586.
［13］Mizuno N, Niwa T, Yotsumoto Y, et al. Impact of drug transporter studies on drug discovery and development［J］. Pharmacol Rev, 2003, 55(3): 425-461.
［14］Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications［J］. Pharm Res, 2007, 24(7): 1227-1251.
［15］Sai Y. Biochemical and molecular pharmacological aspects of transporters as determinants of drug disposition［J］. Drug Metab Pharmacokinet, 2005, 20(2): 91-99.
［16］Tyden E, Bjornstrom H, Tjalve H, et al. Expression and localization of BCRP, MRP1 and MRP2 in intestines, liver and kidney in horse［J］. J Vet Pharmacol Ther, 2010, 33(4): 332-340.
［17］Grube M, Kck K, Karner S, et al. Modification of OATP2B1-mediated transport by steroid hormones［J］. Molecular Pharmacology, 2006, 70(5): 1735-1741.
［18］Ronaldson PT, Ashraf T, Bendayan R. Regulation of multidrug resistance protein 1 by tumor necrosis factor alpha in cultured glial cells: involvement of nuclear factor-kappaB and c-Jun N-terminal kinase signaling pathways［J］. Mol Pharmacol, 2010, 77(4): 644-659.
［19］Qiang F, Lee B J, Lee W, et al. Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats［J］. Eur J Pharm Sci, 2009, 37(3-4): 413-417.
［20］Morgan ET, Lee CM, Nyagode BA. Regulation of drug metabolizing enzymes and transporters in infection, inflammation, and cancer［M］. John Wiley & Sons, Inc., 2008: 123-149.
［21］Harvey RD, Morgan ET. Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents［J］. Clin Pharmacol Ther, 2014, 96(4): 449-457.
［22］Le Vee M, Jouan E, Stieger B, et al. Regulation of drug transporter expression by oncostatin M in human hepatocytes［J］. Biochem Pharmacol, 2011, 82(3): 304-311.
［23］Geier A, Wagner M, Dietrich CG, et al. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration［J］. Biochim Biophys Acta, 2007, 1773(3): 283-308.
［24］Tazoe Y, Hayashi H, Tsuboi S, et al. Reduced folate carrier 1 gene expression levels are correlated with methotrexate efficacy in Japanese patients with rheumatoid arthritis［J］. Drug Metab Pharmacokinet, 2015, 30(3): 227-230.
［25］Lin L, Yee SW, Kim RB, et al. SLC transporters as therapeutic targets: emerging opportunities［J］. Nat Rev Drug Discov, 2015, 14(8):543-560.
［26］Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics［J］. Immunol Rev, 2008, 223: 7-19.
［27］Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution［J］. Eur J Pharm Sci, 2006, 27(5): 425-446.
［28］Fisher CD, Lickteig AJ, Augustine LM, et al. Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats［J］. Eur J Pharmcol, 2009, 613(1-3): 119-127.
［29］Renton KW. Cytochrome P450 regulation and drug biotransformation during inflammation and infection［J］. Curr Drug Metab, 2004, 5(3): 235-243.
［30］Maeda T, Hirayama M, Kobayashi D, et al. Mechanism of the regulation of organic cation/carnitine transporter 1 (SLC22A4) by rheumatoid arthritis-associated transcriptional factor RUNX1 and inflammatory cytokines［J］. Drug MetabDispos, 2007, 35(3): 394-401.
［31］Uno S, Uraki M, Ito A, et al. Changes in mRNA expression of ABC and SLC transporters in liver and intestines of the adjuvant-induced arthritis rat［J］. Biopharm Drug Dispos, 2009, 30(1): 49.
［32］Han HK. Role of transporters in drug interactions［J］. Archiv Pharmacal Res, 2011, 34(11): 501-517.
［33］Momper JD, Tsunoda SM, Ma JD. Evaluation of proposed in vivo probe substrates and inhibitors for phenotyping transporter activity in humans［J］. J Clin Pharmacol, 2016, 56 Suppl 7(S7): S82-98.
［34］Murakami T, Mori N. Involvement of multiple transporters-mediated transports in mizoribine and methotrexate pharmacokinetics［J］. Pharmaceuticals (Basel), 2012, 5(8): 802-836.
［35］Feng Y, Wang C, Liu Q, et al. Bezafibrate-mizoribine interaction: Involvement of organic anion transporters OAT1 and OAT3 in rats［J］. Eur J Pharm Sci, 2016, 81: 119-128.
［36］Ren TL, Han ZJ, Yang CJ, et al. Association of SLC22A4 gene polymorphism with rheumatoid arthritis in the Chinese population［J］. J Biochem Mol Toxicol, 2014, 28(5): 206-210.
［37］Lima A, Bernardes M, Azevedo R, et al. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients［J］. Toxicol Sci, 2014, 142(1): 196-209.
［38］Hediger MA, Clémenon B, Burrier RE, et al. The ABCs of membrane transporters in health and disease (SLC series): Introduction［J］. Mol Aspects Med, 2013, 34(2-3): 95-107.
［39］Neumann J, Rose-Sperling D, Hellmich UA. Diverse relations between ABC transporters and lipids: An overview［J］. Biochim Biophys Acta, 2017, 1859(4): 605-618.
［40］Doerks T, Copley RR, Schultz J, et al. Systematic identification of novel protein domain families associated with nuclear functions［J］. Genome Res, 2002, 12(1): 47-56.
［41］ Kawase A, Norikane S, Okada A, et al. Distinct alterations in ATP-Binding cassette transporter expression in liver, kidney, small intestine, and brain in adjuvant-induced arthritic rats［J］. J Pharm Sci, 2014, 103(8): 2556-2264.
［42］Kawase A, Yoshida I, Tsunokuni Y, et al. Decreased PXR and CAR inhibit transporter and CYP mRNA Levels in the liver and intestine of mice with collagen-induced arthritis［J］. Xenobiotica, 2007, 37(4): 366-374.
［43］Uno S, Kawase A, Tsuji A, et al. Decreased intestinal CYP3A and P-glycoprotein activities in rats with adjuvant arthritis［J］. Drug Metab Pharmacokinet, 2007, 22(4): 313-321.
［44］Marquez B, Van BF. ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions［J］. Curr Drug Targets, 2011, 12(5): 600-620.
［45］Tsujimura S, Saito K, Nawata M, et al. Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis［J］. Ann Rheum Dis, 2008, 67(3): 380-388.
［46］Schwarz UI, Meyer zu Schwabedissen HE, Tirona RG, et al. Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity［J］. Pharmacogenet Genomics, 2011, 21(3): 103-114.
［47］García-Carrasco M, Mendoza-Pinto C, Macias DS, et al. P-glycoprotein in autoimmune rheumatic diseases［J］. Autoimmun Rev, 2015, 14(7): 594-600.
［48］Lima A, Bernardes M, Azevedo R, et al. Pharmacogenomics of methotrexate membrane transport pathway: can clinical response to methotrexate in rheumatoid arthritis be predicted［J］? Int J Mol Sci, 2015, 16(6): 13760-13780.
［49］Mazerska Z, Mroz A, Pawlowska M, et al. The role of glucuronidation in drug resistance［J］. Pharmacol Ther, 2016, 159: 35-55.
［50］Agarwal V, Mittal SK, Misra R. Expression of multidrug resistance-1 protein correlates with disease activity rather than the refractoriness to methotrexate therapy in rheumatoid arthritis［J］. Clin Rheumatol, 2009, 28(4): 427-433.
［51］Rodriguez JM, Monsalves-Alvarez M, Henriquez S, et al. Glucocorticoid resistance in chronic diseases［J］. Steroids, 2016, 115: 182-192.
［52］Liu YM, Chen JW, Chen LX, et al. Overexpression of P-glycoprotein on fibroblast-like synoviocytes in refractory rheumatoid arthritis patients: a potential mechanism for multidrug resistance in rheumatoid arthritis treatment［J］. Genet Mol Res, 2016, 15(2).
［53］Marki-Zay J, Tauberne Jakab K, Szeremy P, et al. MDR-ABC transporters: biomarkers in rheumatoid arthritis［J］. Clin Exp Rheumatol, 2013, 31(5): 779-787.
［54］Chen QX, Hu HH, Zhou Q, et al. An overview of ABC and SLC drug transporter gene regulation［J］. Curr Drug Metab, 2013, 14(2): 253-264.
［55］Sissung TM, Troutman SM, Campbell TJ, et al. Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy［J］. Discov Med, 2012, 13(68): 19-34.

[1]	范杰, 金永明, 江孝龙, 蒋国华. lncRNA HOTAIR调控miR-206影响类风湿关节炎滑膜细胞增殖和凋亡的分子机制研究[J]. 中国临床药理学与治疗学, 2023, 28(7): 736-742.
[2]	陈兰芳，强孚勇，徐亮. 托珠单抗联合改善病情抗风湿药治疗中重度类风湿关节炎短期临床观察[J]. 中国临床药理学与治疗学, 2018, 23(12): 1386-1391.
[3]	伍嘉琪，杨俏雯，陈秀敏，黄闰月，黄清春，赵越，吴晓东. 艾拉莫德联合甲氨蝶呤治疗类风湿关节炎有效性和安全性的系统评价和Meta分析[J]. 中国临床药理学与治疗学, 2018, 23(10): 1132-1140.
[4]	杨红，林杉，杨宏，谢晓薇，王新. 艾拉莫德对类风湿关节炎患者血管内皮生长因子及色素上皮衍生因子表达的影响[J]. 中国临床药理学与治疗学, 2017, 22(1): 68-71.
[5]	李小心, 王田玲, 余菲, 邵体红, 陈兰芳, 毛桐俊, 陆进明, 徐亮. 类风湿关节炎缓解后维持治疗方案的研究[J]. 中国临床药理学与治疗学, 2015, 20(7): 797-802.
[6]	刘东阳, 苏金梅, 宋瀚麟, 陈嘉, 刘洋, 幺雪婷, 宋玲, 江骥, 胡蓓. 甲氨蝶呤及其活性代谢产物在类风湿关节炎患者体内的药动学模型研究[J]. 中国临床药理学与治疗学, 2015, 20(5): 571-577.
[7]	蔡质其, 张育, 张学增, 沈维干. 甲氨蝶呤对炎性细胞因子及丝裂原活化蛋白激酶信号通路的影响[J]. 中国临床药理学与治疗学, 2014, 19(12): 1347-1351.
[8]	张晓清, 刘思博, 窦云鹏, 杜雨轩, 袁慧慧, 赵文明. pCMV-DKK1/IL10双表达核酸疫苗的构建及其免疫保护效果研究[J]. 中国临床药理学与治疗学, 2014, 19(11): 1211-1217.
[9]	刘青松, 朱兴春, 蒋红, 蔡燕, 袁国华, 杨明辉, 张均, 李君安, 唐中. 丹参注射液诱导类风湿关节炎成纤维样滑膜细胞NF-κB表达研究[J]. 中国临床药理学与治疗学, 2012, 17(8): 846-850.
[10]	牛芳, 周芳, 吴晓兰, 王广基. 血脑屏障上ABC转运体与中枢神经系统疾病相关性的研究进展[J]. 中国临床药理学与治疗学, 2012, 17(2): 225-233.
[11]	荣超, 陈飞虎, 江晟, 胡伟, 葛金芳, 张晨晨, 吴繁荣. 胞外酸化对体外培养大鼠关节软骨细胞增殖与凋亡及组织蛋白酶K mRNA表达的影响[J]. 中国临床药理学与治疗学, 2012, 17(1): 34-39.
[12]	李丹丹, 陆进明. 糖皮质激素在类风湿关节炎中的应用进展[J]. 中国临床药理学与治疗学, 2012, 17(1): 116-120.
[13]	任传永, 徐亮, 宣丹, 李志, 盛君, 陆进明. 血清铁蛋白在风湿性疾病诊断及治疗中的价值[J]. 中国临床药理学与治疗学, 2010, 15(6): 682-685.
[14]	张鸽, 吴玉林. 骨桥蛋白在类风湿关节炎发病机理中的研究进展[J]. 中国临床药理学与治疗学, 2007, 12(5): 488-492.
[15]	刘继红, 李卫东, 林志彬. 类风湿关节炎细胞凋亡的研究现状[J]. 中国临床药理学与治疗学, 2003, 8(2): 232-236.

类风湿关节炎下转运体表达及活性的变化

Changes of transporters expression and activity in rheumatoid arthritis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价